5-(5-chloro-3-methyl-1H-indazol-4-yloxy)-isophthalonitrile | 1123741-48-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(5-chloro-3-methyl-1H-indazol-4-yloxy)-isophthalonitrile
• 英文别名: 5-[(5-chloro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile；5-[(5-chloro-3-methyl-2H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile
• CAS: 1123741-48-9
• 化学式: C₁₆H₉ClN₄O
• 分子量: 308.727
• InChiKey: VXGYYFMKSYJDOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  85.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(3-methyl-1H-indazol-4-yloxy)-isophthalonitrile 在 磺酰氯 、 溶剂黄146 作用下， 反应 6.0h， 以35%的产率得到5-(5-chloro-3-methyl-1H-indazol-4-yloxy)-isophthalonitrile
  参考文献：
  名称：

  Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays

  摘要：

  A major problem associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV is their lack of resilience to mutations in the reverse transcriptase (RT) enzyme. Using structural overlays of the known inhibitors efavirenz and capravirine complexed in RT as a starting point, and structure-based drug design techniques, we have created a novel series of indazole NNRTIs that possess excellent metabolic stability and mutant resilience.

  DOI：

  10.1021/jm801322h

文献信息

• Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays
  作者：Lyn H. Jones、Gill Allan、Oscar Barba、Catherine Burt、Romuald Corbau、Thomas Dupont、Thorsten Knöchel、Steve Irving、Donald S. Middleton、Charles E. Mowbray、Manos Perros、Heather Ringrose、Nigel A. Swain、Robert Webster、Mike Westby、Chris Phillips

  DOI：10.1021/jm801322h

  日期：2009.2.26

  A major problem associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV is their lack of resilience to mutations in the reverse transcriptase (RT) enzyme. Using structural overlays of the known inhibitors efavirenz and capravirine complexed in RT as a starting point, and structure-based drug design techniques, we have created a novel series of indazole NNRTIs that possess excellent metabolic stability and mutant resilience.